Lynparza 50mg capsules | Olaparib |Apple Pharmaceuticals

1. Lynparza 50mg | Lynparza 50mg Capsules   Apple Pharmaceuticals

2. Lynparza 50mg Capsules • Lynparza is a type of targeted therapy called a PARP (oral poly (adenosine diphosphate–ribose) polymerase inhibitor)which has promising anti neoplasticaction in patients with metastatic breast cancer and a germline BRCA mutation. • Lynparza 50mg is an enzyme included in DNA repair and will act against cancers in people with hereditary BRCA1 or BRCA2 mutations, which involve some ovarian, breast and prostate cancer • Lynparza 50mg Capsules is a prescription drug which used under the supervision of medical practioners

3. INDICATION • Lynparza 50 capsules is used for the treatment in patients with first line maintenance BRCAm advanced ovarian cancer • Lynparza 50mg is used for the treatment in patients with maintenance recurrent ovarian cancer. • Lynparza is used for the treatment in patients withadvancedgBRCAm ovarian cancer • Lynparza is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.

4. DOSAGE • Ovarian cancer : • Maintenance treatment of recurrent ovarian cancer: • The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID • The capsules usual dose is 400mg (eight 50mg- mg capsules) PO BID • Continue treatment until disease progression or unacceptable toxicity. • Maintenancetreatment for advanced BRCA-mutated ovarian cancer • The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID • Follow the treatment until disease progression,lynparza undesirable toxicity or completion of 2 years of treatment • • Patients with full response (no radiologic evidence): discontinue treatment • • Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years

5. MECHANISM • Olaparib 50mg capsules belongs to targeted therapy. Olaparib is also called as poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, involving PARP1, PARP2, and PARP3. PARP enzymes are containing in DNA transcription, cell cycle regulation, and DNA repair. • Olaparib  belongs to potent oral PARP inhibitor which induces synthetic fatality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA cutsthat cannot be accurately repaired, which causesdivision of cellular homeostasis and cell death

6. ADME • Absorption: Maximum plasma concentration 1 to 3 hours • Distribution: volume of distribution 167 +/-196 L, plasma protein binding is 82% • Metabolism: Primarily metabolised by CYP3A4 • Elimination: Excreted through the urine 44% and 42% through the feces. • Half – life of Lynparza 11.9 hours PRECAUTION • • Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia. • • Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.

7. DRUG INTERACTION • Concomitant use with myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. • Lynparzacombination with strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib 50mg plasma concentration. MISSED DOSE • If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule. • Consult doctors regarding missed dose.

9. SIDE EFFECTS • Common side effects for patients taking Olaparib: • • Decreased white blood cell count • • Abdominal pain • • Vomiting • • Upper respiratory tract infection • • Anemia • • Decreased neutrophils • • Musculoskeletal pain • • Diarrhea • • Decreased platelet count • • Decreased Haemoglobin • • Nausea • • Fatigue (including weakness) • • Increased serum creatinine • • Myalgia • • Headache • • Skin rash • • Back pain • • Taste changes • • Cough

10. Contact Us phone No      :9987711567 Email             :info@myapplepharma.com website https://myapplepharma.com/lynparza-50mg.php https://myapplepharma.com/olaparib.php